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and Partners Enriching the Pipeline for Innovative ProductsInnovation and technical advances in dermatology are advancing at a
robust pace due to an accelerating rate of fundamental scientiﬁc
discoveries, which are the substrate for fueling healthy product
innovation. With dermatologic products and practices experiencing a
surge in popularity worldwide, venture capitalists and ﬁnancial partners
are seeking opportunities to invest. This landscape beckons entrepre-
neurship, providing a fertile ground for those inspired to act. As assertedat
the 2015 Dermatology Entrepreneurship Conference by Howard Murad,
MD, FAAD, founder and CEO of Murad, Inc., for those interested in
entrepreneurship there are resources available, including advice from
many: "But don’t listen to the naysayers, particularly if one of them is you.
If you’re really interested, and you have the passion to develop a product
or system, give yourself permission to be successful."Dermatology Entrepreneurship Conference
To help and encourage researchers, clinicians, and other colleagues to
take advantage of this favorable climate toward dermatologic product and
service innovation, anassemblyof theﬁeld’s top thought leaders, innovators,
corporate partners, and investors came together at the Dermatology
Entrepreneurship Conference (DEC) to discuss what it takes to enter and
succeed in the entrepreneurial world. This inaugural conference took place
on March 19 just before American Academy of Dermatology 2015 Annual
Meeting in San Francisco and was organized by Advancing Innovation in
Dermatology, Inc. (AID). AID is a nonproﬁt organization founded by
dermatologists with a mission to help grow an ecosystem for creating and
bringing to market an increased number of innovative and scientiﬁcally-
based products that substantially improve dermatologic health.
As background on the DEC, AID created and hosts the Dermatology
Summit (DS)meeting each January around the JP Morgan Healthcare
Conference, where companies and investors gather to learn and
exchange ideas about business opportunities in dermatology. Here
innovative product ideas have typically advanced to the clinical
proof-of-concept or early commercialization stages. As an important
complement to the DS, AID launched this year the DEC, which
speciﬁcally concentrates on what is required during the early phases
of product development (Figure 1). The DEC program was structured
to cover the two parallel and interacting activity steams that mutually
enable progression from idea to product. First, DEC program speakers
shared their experience and wisdom on elements of the technical
stream, including scientiﬁc discovery, invention, and translation into
the clinic. In addition, the ﬁnancial streamwas discussed extensively,
including expert panels in the key areas of ﬁnancing and intellectual
propertyprotection. Inaddition to theseeducational components, theDEChttp://dx.doi.org/10.1016/j.ijwd.2015.08.004
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).also serves as a networking event for cultivating a supportive entrepre-
neurial ecosystem for its registrants, which numbered over 300 this
inaugural year. About one-third of the attendees were women and about
one-half were dermatologists. Women’s Dermatologic Society past
presidents Lynn Drake, MD, FAAD and Barbara Gilchrest, MD, FAAD
servedon themeeting’sDermatologyAdvisoryBoard,whichalso included
Tina Alster, MD, FAAD,Mat Avram,MD, JD, FAAD, Alice Gottlieb,MD, PhD,
FAAD, Gary Lask, MD, FAAD, Mark Lebwohl, MD, FAAD, and Ken
Washenik, MD, PhD, FAAD as board members.The Technical Stream
Amore robust technical stream fordermatology is beingenabledbyan
accelerating rate of scientiﬁc breakthroughs resulting in more in-depth,
accurate, and precise understandings of mechanisms underlying skin
diseases and dysfunctions. This importantly provides novel targets for
product innovation. Keynote speakers featured an impressive roster of
dermatologic scientiﬁc inventors, entrepreneurs, and business leaders
describing the process and path to innovation. Doug Lowy, MD, DABD,
Acting Director of the National Cancer Institute andwhose research led to
thedevelopmentof theHPVvaccine, toldparticipants that, “Agoodpart of
entrepreneurship is doing what needs to be done even when you’re not
comfortable with it. If you’re not an expert in your ﬁeld of invention,
become one.” Rox Anderson, MD, FAAD, Professor at Harvard Medical
School and MIT and a world-renowned leader in device innovation,
counseled that meaningful creation requires “kissing lots of frogs.” He
suggested that clinicians, though, are very good about knowing which
“frogs” have the potential to become “princes”.
When it comes to molding an idea into something substantive,
getting feedback early on is a key step in taking an idea to a product.
Camille Samuels, MBA, a partner with the venture capital ﬁrm
Venrock and with multiple astute investments in dermatology,
encouraged attendees to set aside the notion that your entrepreneur-
ial “baby” must be perfect before you go out and get input. For
products not requiring FDA approval Katie Rodan, MD, FAAD,
co-founder of Rodan & Fields and its blockbuster Proactiv® product,
advised trying to sell your product earlier rather than later to validate
your idea and test your distribution channel.
By nature, academics and scientists are accustomed to working
alone. However, to succeed as an entrepreneur requires thinking
about a different model, which is one that involves other people and
the willingness to share the credit. Seth Orlow, MD, PhD, FAAD,
Professor and Chair of NYU’s Dermatology Department and Senior
Advisor with Pharus Advisors, stated “Academics, know yourmatologic Society. This is an open access article under the CC BY-NC-ND license
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Figure 1. The product development ecosystem. Product development is a complex continuum from discovery through commercialization, which has multiple contributors and
stakeholders that must effectively interact. The process involves a technical stream and a ﬁnancial stream, which aremutually enabling. The Dermatology Entrepreneurship Conference
and Dermatology Summit meetings focus on education and networking for the earlier stage and later stage of dermatology product development, respectively.
178 Editorialstrengths. For what you don't know or can’t do, ﬁnd otherswho can ﬁll
your gaps.” Dr. Neal Walker, MBA, FAAD, founder and CEO of Aclaris
Therapeutics, Inc. added, “Your investors are partners. Choose them
wisely for all of their skills and attributes they bring and not just for
their money.”
The Financial Stream
The ﬁnancial stream fuels moving an idea to a product. Although
dermatology is increasingly accepted as a high-growth area attractive
for investment, entrepreneurs still need to know how to package their
particular “story” in a way that speaks to and appeals to investors and
corporate partners. First and foremost, there must be a case
demonstrating to the investors that they can get a desired return on
their money. Thus, the would-be entrepreneur must clearly convey
how the idea will create value and how this value will be preserved
during its product development. For example, it is frequently crucial
to show intellectual property protection, and for products needing
market registration to deﬁne a feasible path to regulatory approval.
The Dermatology Shark Tank
Having the idea for a product or service is only the genesis of
entrepreneurship. So how do you take the idea and present the “right”
criteria that investors will look at and ultimately choose to sink their
capital into? Recognizing the need to educate burgeoning entrepre-
neurs on the structured processes that shepherd breakthrough ideas
towards commercialization, the DEC gave selected applicants the
platform to present their ideas in front of renowned panel of venture
capitalists as judges. Applicants, who were invited to present
information that they considered non-conﬁdential and non-propri-
etary in this public forum, were divided into two categories based on
the level of development: the Dermatology Shark Tank was for
products or services at a more advanced stage and a Poster Business
Competition was for those at an earlier level.These two business competitions had submissions in ﬁve catego-
ries: devices, diagnostics, drugs, over-the-counter products, and
business services. Each applicant wrote responses on ﬁve topics
typically important in a pitch to potential investors. This was designed
to be a valuable teaching exercise in the business and commercial
aspects of medical products and services, which doctors and scientists
are typically not trained to research and analyze. The response
categories included the following key areas:
1. The problem. Deﬁne the dermatologic clinical problem worth
solving, the current solutions, and the strengths and weak-
nesses of the current solutions.
2. Your solution. Describe how your solution is it different and
explain why it is valuable.
3. Clinical hypothesis. Summarize the scientiﬁc or technical basis
of what you are developing, and brieﬂy provide evidence that
supports its approach as useful and feasible.
4. Product proﬁle and development plan. Describe the product
(i.e. some information of what it is) and what stage it is in (e.g.
concept, preclinical, prototype, closed beta, etc.). Also please
include the next major milestone (and costs to achieve that
milestone) in the product’s development.
5. Value of your solution. What is your rough estimate of the
yearly market revenue potential (and what are some for the
basic assumptions underlying that estimate).
Four ﬁnalists were selected to “jump into” the Shark Tank for a
chance at the $15,000 cash prize. The winner was “Restoring the Skin
Microbiome: Ammonia Oxidizing Bacteria in Dermatology” submitted
by Larry Weiss, MD, chief medical ofﬁcer with AOBiome, LLC. Sixteen
ﬁnalists were selected for the Poster Business Competition. Two were
chosen to each receive a $2,500 cash prize: “Novel medical device
treatment for onychomycosis (room temperature plasma gas)”
submitted by Jeffrey Roe, PhD at the startup ﬁrm, DeviceFarm, Inc.,
and “Point of care diagnosis for Kaposi's sarcoma using portable
confocal microscopy” developed by Esther Freeman, MD, PhD, FAAD,
179Editorialwith the Department of Dermatology at Harvard Medical School and
the MGH.
In summary, this is an opportune time with dermatology well
positioned for further development of impactful products. This is the
result of a conﬂuence of accelerating strong science as the basis to
address unmet medical needs and the perception by investors and
companies that dermatology is an attractive ﬁeld to fund. Given
today’s environment, it is also a time to cultivate and support young
entrepreneurs who have an interest in and understanding ofdermatology business innovation. This is an important concept to us
at AID because robust and sustainable pipelines ultimately depend on
inspired people to create andmove along creative ideas that can fulﬁll
unmet clinical needs. It is this ﬂow of impactful product and service
innovations can help ensure that dermatology remains a vibrant ﬁeld
that will continually have better solutions for those seeking care for
their dermatologic needs.
William Ju, MD, FAAD
